Searchable abstracts of presentations at key conferences on calcified tissues

ba0003pp359 | Osteoporosis: treatment | ECTS2014

Ten year alendronate use does not adversely affect bone quality compared to 5 years use: a human iliac crest biopsy study

Hassler Norbert , Gamsjaeger Sonja , Hofstetter Birgit , Brozek Wolfgang , Misof Barbara , Roschger Paul , Klaushofer Klaus , Paschalis Eleftherios

Bisphosphonates (BPs) including alendronate (ALN) are the most widely prescribed therapy for post-menopausal osteoporosis. Despite their overall excellent safety record and efficacy in reducing fractures, concerns have been expressed lately regarding potential detrimental effects due to prolonged bone turnover reduction, although no definite cause–effect relationship has been established to date. The purpose of the present study was to determine bone material quality by R...

ba0004p120 | (1) | ICCBH2015

Fracture incidence and bisphosphonate therapy in boys with Duchenne Muscular Dystrophy

Crabtree Nicola , Hogler Wolfgang , Sahota Jaskiran , Chapman Dee , Walford Jacky , Roper Helen , Willis Tracy , Shaw Nicholas

Background: DMD is a progressive neuromuscular disease often treated with oral glucocorticoids (GC) to prolong ambulation and maintain cardiovascular function. However, the osteotoxic GC effects often result in a skeleton prone to fractures. DMD boys presenting with fractures are treated with bisphosphonates (BP) but evidence of beneficial effects is limited. The aim of this work was to review the use of intravenous BPs in a group of severely affected boys with fractures.<...

ba0005p261 | Muscle, physical activity and bone | ECTS2016

Bone and muscle metabolism in lung transplant recipients

Foger-Samwald Ursula , Petrikic Aleksandra , Gruther Wolfgang , Ebenbichler Gerold , Kudlacek Stefan , Pietschmann Peter

Although it is well established, that quality of life improves in patients after lung transplantation (LTx), severe musculoskeletal complications may develop. The aim of this study was to evaluate differences in the muscle markers Myostatin and Follistatin and the bone markers Dickkopf-1 (DKK1), Sclerostin (SOST) and Periostin between LuTx recipients and healthy controls. From 38 LTx patients blood samples were taken when discharged from hospital (LTx1) and 6-9 months after di...

ba0005p314 | Osteoporosis: evaluation and imaging | ECTS2016

Inducing osteoporosis in a large animal model: influence of ovariectomy, diet and corticoid therapy

Sender Jonas , El Khassawna Thaqif , Erdmann Georg , Bocker Wolfgang , Krombach Gabriele A. , Langheinrich Alexander C. , Kampschulte Marian

Purpose: The aim of our study is a micro-CT-based, longitudinal characterisation of ovariectomy, multideficient diet and corticoid therapy impact on the ossal microarchitecture.Materials and methods: Four randomized groups were formed out of 32 adult female merino land sheep:1. control2. ovariectomized (OVX)3. OVX+multideficient diet (OVX-D)4. OVX-D+320 mg methylp...

ba0005p321 | Osteoporosis: evaluation and imaging | ECTS2016

The T-score standard in osteoporotic sheep model: insight into independent reference group

Khassawna Thaqif El , Engelhardt Markus , Weisweiler David , Bocker Wolfgang , Schmitt Jakob , Heiss Christian

FDA guidelines recommend the sheep as large animal model for osteoporosis. Studies of osteoporosis induction use dual energy x-ray absorptiometry (DEXA) to evaluate bone status. Experimentally, the T-score is calculated based on reference bone mineral density (BMD) values of animals before treatment (0 M). Whereas clinically the reference BMD represents values of an independent group of patients around 30 years old. The study hypothesize that the use of additional ind...

ba0005p328 | Osteoporosis: pathophysiology and epidemiology | ECTS2016

Use of proton pump inhibitors and hip re-fractures among Austrian hip fracture patients

Brozek Wolfgang , Reichardt Berthold , Zwerina Jochen , Peter Dimai Hans , Klaushofer Klaus , Zwettler Elisabeth

We retrospectively analyzed the incidence of hip re-fractures in Austrian hip fracture patients devoid of anti-osteoporotic drug treatment, taking vs not taking proton pump inhibitors (PPIs).For 31,668 patients ≥50 years sustaining a hip fracture in Austria between July 2008 and December 2010, information on hip re-fractures with follow-up until June 2011 and on filed prescriptions of PPIs and anti-osteoporotic drugs between July 2007 and June 2011...

ba0006p031 | (1) | ICCBH2017

Valproic acid induces Fanconi syndrome and reversible hypophosphataemic rickets via upregulation of fibroblast growth factor 23

Saraff Vrinda , Padidela Raja , Mushtaq Talat , Sakka Sophia , Mughal Zulf , Hogler Wolfgang

Background: Valproic Acid (VPA) is a commonly used antiepileptic drug in the management of childhood epilepsy. Renal dysfunction presenting as Fanconi syndrome (FS) is a rare side effect of VPA use. This can lead to renal tubular phosphate loss, resulting in hypophosphataemic rickets, low bone mass and fractures. We report 6 children with VPA induced FS from three tertiary paediatric metabolic bone centres across England.Presenting problem: P1: Global de...

ba0006p085 | (1) | ICCBH2017

Cumulative radiation exposure from diagnostic imaging and associated lifetime cancer risk in children with Osteogenesis Imperfecta

Thorby-Lister Amy , Hogler Wolfgang , Hodgson Kirsten , Crabtree Nicola , Shaw Nick , Saraff Vrinda

Background and objectives: Fracture rate in Osteogenesis Imperfecta (OI) is highest between 0 and 19 years, and associated radiation exposure also carries the highest lifetime cancer risk. Here, we investigate the cumulative effective radiation dose (E) and lifetime cancer risk from diagnostic imaging in OI children. We also explore the hypothesis that negative family history of OI will increase injury-related, fracture-negative X-rays due to parental anxiety.<p class="abs...

ba0006p094 | (1) | ICCBH2017

Bone health assessment in children with thalassaemia major

Sakka Sophia , Crabtree Nicola , Kumar Aswath , Velangi Mark , Hogler Wolfgang , Shaw Nick J.

Objectives: Bone disease is a long-term complication in patients with thalassaemia and therefore current UK guidelines recommend biannual bone density assessment from the age of 10 years. The aim of this study was to evaluate bone health in children with thalassaemia major.Methods: Twenty-nine patients (11 boys) with a mean (S.D.) age of 13.07 year (2.29) with thalassaemia major had measurement of lumbar spine BMAD (L2-L4) and of total bod...